Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TRPA1 | O75762 | 2/20 | 0.45 |
| ▸ | TRPM8 | Q7Z2W7 | 2/20 | 0.45 |
| ▸ | GBA1 | P04062 | 6/20 | 0.34 |
| ▸ | CA1 | P00915 | 1/20 | 0.33 |
| ▸ | CA2 | P00918 | 1/20 | 0.33 |
| ▸ | CA4 | P22748 | 1/20 | 0.33 |
| ▸ | PYGL | P06737 | 2/20 | 0.32 |
| ▸ | GAA | P10253 | 2/20 | 0.32 |
| ▸ | SI | P14410 | 1/20 | 0.32 |
| ▸ | GBA2 | Q9HCG7 | 1/20 | 0.32 |
| ▸ | GLB1 | P16278 | 1/20 | 0.32 |
| ▸ | EPHX2 | P34913 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL22739224 | 0.82 | TRPA1 (0.42) | TRPA1TRPM8CA1CA2CA4 | |
| SCHEMBL13225335 | 0.82 | TRPA1 (0.42) | TRPA1TRPM8CA1CA2CA4 | |
| SCHEMBL3479924 | 0.81 | TRPA1 (0.40) | TRPA1TRPM8GBA1CA1CA2 | |
| SCHEMBL12159671 | 0.81 | TRPA1 (0.45) | TRPA1TRPM8CA1CA2CA4 | |
| SCHEMBL31516173 | 0.81 | TRPA1 (0.45) | TRPA1TRPM8CA1CA2CA4 | |
| SCHEMBL13916212 | 0.81 | TRPA1 (0.40) | TRPA1TRPM8GBA1CA1CA2 | |
| SCHEMBL3249131 | 0.81 | TRPA1 (0.45) | TRPA1TRPM8CA1CA2CA4 | |
| SCHEMBL27732658 | 0.81 | TRPA1 (0.45) | TRPA1TRPM8CA1CA2CA4 | |
| SCHEMBL18644147 | 0.81 | TRPA1 (0.45) | TRPA1TRPM8CA1CA2CA4 | |
| SCHEMBL899282 | 0.80 | TRPA1 (0.33) | TRPA1TRPM8GBA1SIEPHX2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7767012-B2 | Recording liquid, liquid cartridge, liquid discharge device, and liquid discharge method | SONY CORPORATION (JP) | 2010-08-03 | — | — | US | disclosed |
| US-20070139500-A1 | RECORDING LIQUID, LIQUID CARTRIDGE, LIQUID DISCHARGE DEVICE, AND LIQUID DISCHARGE METHOD | SONY CORPORATION (JP) | 2007-06-21 | — | — | US | disclosed |
| US-20040091515-A1 | Noxious-insect repellent | KANEBO, LTD. | 2004-05-13 | — | — | US | disclosed |
| US-6686396-B2 | NO OFFENSIVE ODOR AND EXHIBIT EXCELLENT NOXIOUS-INSECT REPELLING EFFECT AND DURABILITY | KANEBO, LTD. (JP) | 2004-02-03 | — | — | US | disclosed |
| US-6677384-B1 | CARBOCYCLIC ALCOHOLS SUCH AS 2-HYDROXYMETHYL-3,3,5-TRIMETHYL-CYCLOHEXANOL USED AS ODORLESS, DURABLE LOTIONS TO PREVENT DISEASES | KANEBO, LTD. (JP) | 2004-01-13 | — | — | US | disclosed |
| US-20020143070-A1 | Noxious-insect repellent | KANEBO, LTD. | 2002-10-03 | — | — | US | disclosed |
| US-6372804-B1 | HYDROXYALKYLCYCLOALKANOLS REPELLENTS | KANEBO, LTD. (JP) | 2002-04-16 | — | — | US | disclosed |
| US-6130255-A | EXPOSING NOXIOUS INSECTS TO REPELLENT COMPRISING 2-(1-HYDROXYALKYL)-CYCLOALKANOLS HAVING NO OFFENSIVE ODOR | KAO CORPORATION (JP) | 2000-10-10 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20020143070-A1 | Noxious-insect repellent | OPRM1, OPRD1, L3MBTL1 | TRPA1 13/4885TRPM8 156/4885GBA1 4407/4885 |
| US-20040091515-A1 | Noxious-insect repellent | OPRM1, OPRD1, OPRK1 | TRPA1 9/4885TRPM8 270/4885GBA1 4620/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.